The exploration of macrocycles for drug discovery - an underexploited structural class

被引:1091
作者
Driggers, Edward M. [1 ]
Hale, Stephen P. [1 ]
Lee, Jinbo [1 ]
Terrett, Nicholas K. [1 ]
机构
[1] Ensemble Discovery, Cambridge, MA 02139 USA
关键词
D O I
10.1038/nrd2590
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Macrocyclic natural products have evolved to fulfil numerous biochemical functions, and their profound pharmacological properties have led to their development as drugs. A macrocycle provides diverse functionality and stereochemical complexity in a conformationally pre-organized ring structure. This can result in high affinity and selectivity for protein targets, while preserving sufficient bioavailability to reach intracellular locations. Despite these valuable characteristics, and the proven success of more than 100 marketed macrocycle drugs derived from natural products, this structural class has been poorly explored within drug discovery. This is in part due to concerns about synthetic intractability and non-drug-like properties. This Review describes the growing body of data in favour of macrocyclic therapeutics, and demonstrates that this class of compounds can be both fully drug-like in its properties and readily prepared owing to recent advances in synthetic medicinal chemistry.
引用
收藏
页码:608 / 624
页数:17
相关论文
共 105 条
[1]   Mechanism of action of oritavancin and related glycopeptide antibiotics [J].
Allen, NE ;
Nicas, TI .
FEMS MICROBIOLOGY REVIEWS, 2003, 26 (05) :511-532
[2]   Comparison of the ATP binding sites of protein kinases using conformationally diverse bisindolylmaleimides [J].
Bartlett, S ;
Beddard, GS ;
Jackson, RM ;
Kayser, V ;
Kilner, C ;
Leach, A ;
Nelson, A ;
Oledzki, PR ;
Parker, P ;
Reid, GD ;
Warriner, SL .
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 2005, 127 (33) :11699-11708
[3]   Rapamycin analogs with differential binding specificity permit orthogonal control of protein activity [J].
Bayle, JH ;
Grimley, JS ;
Stankunas, K ;
Gestwicki, JE ;
Wandless, TJ ;
Crabtree, GR .
CHEMISTRY & BIOLOGY, 2006, 13 (01) :99-107
[4]   3-aminopyrrolidinone farnesyltransferase inhibitors: Design of macrocyclic compounds with improved pharmacokinetics and excellent cell potency [J].
Bell, IM ;
Gallicchio, SN ;
Abrams, M ;
Beese, LS ;
Beshore, DC ;
Bhimnathwala, H ;
Bogusky, MJ ;
Buser, CA ;
Culberson, JC ;
Davide, J ;
Ellis-Hutchings, M ;
Fernandes, C ;
Gibbs, JB ;
Graham, SL ;
Hamilton, KA ;
Hartman, GD ;
Heimbrook, DC ;
Homnick, CF ;
Huber, HE ;
Huff, JR ;
Kassahun, K ;
Koblan, KS ;
Kohl, NE ;
Lobell, RB ;
Lynch, JJ ;
Robinson, R ;
Rodrigues, AD ;
Taylor, JS ;
Walsh, ES ;
Williams, TM ;
Zartman, CB .
JOURNAL OF MEDICINAL CHEMISTRY, 2002, 45 (12) :2388-2409
[5]  
Blondeau Joseph M, 2002, Expert Opin Pharmacother, V3, P1131, DOI 10.1517/14656566.3.8.1131
[6]   Resisting degradation by human elastase: Commonality of design features shared by 'canonical' plant and bacterial macrocyclic protease inhibitor scaffolds [J].
Brauer, Arnd B. E. ;
McBride, Jeffrey D. ;
Kelly, Geoff ;
Matthews, Stephen J. ;
Leatherbarrow, Robin J. .
BIOORGANIC & MEDICINAL CHEMISTRY, 2007, 15 (13) :4618-4628
[7]  
Breinbauer R, 2002, ANGEW CHEM INT EDIT, V41, P2879
[8]  
Butler MS, 2005, NAT PROD REP, V22, P162, DOI 10.1039/b402985m
[9]   Synthesis and activity of conformationally-constrained macrocyclic norstatine-based inhibitors of HIV protease [J].
Chen, JJ ;
Coles, PJ ;
Arnold, LD ;
Smith, RA ;
MacDonald, ID ;
Carriere, J ;
Krantz, A .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1996, 6 (04) :435-438
[10]   Novel potent hepatitis C virus NS3 serine protease inhibitors derived from proline-based macrocycles [J].
Chen, KX ;
Njoroge, FG ;
Arasappan, A ;
Venkatraman, S ;
Vibulbhan, B ;
Yang, WY ;
Parekh, TN ;
Pichardo, J ;
Prongay, A ;
Cheng, KC ;
Butkiewicz, N ;
Yao, NH ;
Madison, V ;
Girijavallabhan, V .
JOURNAL OF MEDICINAL CHEMISTRY, 2006, 49 (03) :995-1005